DOI QR코드

DOI QR Code

Application of Radiofrequency Ablation to Thyroid Cancer: Past, Present, and Future

갑상선암에 대한 고주파 절제 적용의 과거, 현재, 그리고 미래

  • Ji-hoon Kim (Department of Radiology, Seoul National University Hospital, College of Medicine of Seoul National University)
  • 김지훈 (서울대학교 의과대학 서울대학교병원 영상의학과)
  • Received : 2023.06.16
  • Accepted : 2023.07.20
  • Published : 2023.09.01

Abstract

Thyroid cancer, characterized by high incidence rates, good prognosis, and frequent recurrence, is typically treated surgically. However, since the early 2000s, radiofrequency ablation, which is commonly utilized in liver, lung, and kidney cancers, is being performed for management of primary and recurrent thyroid cancers. Many studies have focused on inoperable cases of low-risk papillary microcarcinoma (≤ 1 cm) and some have investigated its role in larger lesions (up to 4 cm). Overall, these studies have reported positive results. Radiofrequency ablation for recurrent cancer has primarily been performed for locally recurrent cervical cancer, and this therapeutic approach has been attempted for treatment of distant metastases in lungs and bones, with encouraging outcomes. A growing global trend, particularly in South Korea, the United States, and Europe supports radiofrequency ablation for thyroid cancer. However, this therapy is currently not recognized as a treatment option recommended by universally accepted clinical guidelines such as those established by the National Comprehensive Cancer Network. Based on past efforts and future research, radiofrequency ablation is expected to play a key role in thyroid cancer treatment in the near future.

발생률이 높고, 예후는 좋지만 재발을 잘하는 경향이 있는 갑상선암에서도 전통적인 치료법은 수술이다. 하지만, 2000년대 초반부터, 간암, 폐암, 신장암에서와 마찬가지로 고주파 절제술이 원발 갑상선암 및 재발 갑상선암에 적용되기 시작했다. 원발암에서는 1 cm 이하 크기의 미세유두암 저위험군에서 수술 불가능한 경우에 대한 많은 연구가 이뤄져 왔고, 1 cm보다 더 크고 4 cm 이하의 다양한 군에 대해서도 일부 연구가 시행되었으며, 전반적으로 모두 양호한 결과를 보고하였다. 재발암에 대해서도 주로는 국소 경부 재발암에 고주파 절제술이 시행되었으며, 일부 폐, 뼈 등의 원격 전이에 대해서도 시도되었고, 전반적으로 양호한 결과가 보고되었다. 최근 들어, 한국, 미국, 유럽 등 각지에서 갑상선암의 고주파 절제술에 대해 옹호하는 움직임이 있다. 하지만, 미국 국립 종합 암 네트워크(National Comprehensive Cancer Network) 등의 중립적인 임상지침에는 고주파 절제술이 아직 인정되지는 않은 상태이다. 지금까지의 노력들과 미래의 연구를 바탕으로 향후 가까운 미래에 갑상선암의 치료에 있어 고주파 절제술이 적절한 자리매김을 할 것으로 전망한다.

Keywords

References

  1. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016;375:614-617 
  2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133 
  3. Ito Y, Miyauchi A. Active surveillance of low-risk papillary thyroid microcarcinomas. Gland Surg 2020;9:1663-1673 
  4. Kim TM, Kim JH, Yoo RE, Kim SC, Chung EJ, Hong EK, et al. Persistent/recurrent differentiated thyroid cancer: clinical and radiological characteristics of persistent disease and clinical recurrence based on computed tomography analysis. Thyroid 2018;28:1490-1499 
  5. Kim JH, Yoo WS, Park YJ, Park DJ, Yun TJ, Choi SH, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. Radiology 2015;276:909-918 
  6. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 2001;130:971-977 
  7. Pacella CM, Bizzarri G, Spiezia S, Bianchini A, Guglielmi R, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. Radiology 2004;232:272-280 
  8. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006;244:296-304 
  9. Papini E, Guglielmi R, Gharib H, Misischi I, Graziano F, Chianelli M, et al. Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk. Thyroid 2011;21:917-920 
  10. Valcavi R, Piana S, Bortolan GS, Lai R, Barbieri V, Negro R. Ultrasound-guided percutaneous laser ablation of papillary thyroid microcarcinoma: a feasibility study on three cases with pathological and immunohistochemical evaluation. Thyroid 2013;23:1578-1582 
  11. Zhou W, Jiang S, Zhan W, Zhou J, Xu S, Zhang L. Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma: preliminary results. Eur Radiol 2017;27:2934-2940 
  12. Yue W, Wang S, Yu S, Wang B. Ultrasound-guided percutaneous microwave ablation of solitary T1N0M0 papillary thyroid microcarcinoma: initial experience. Int J Hyperthermia 2014;30:150-157 
  13. Jeon EJ, Shon HS, Jung ED. Radiofrequency ablation for the papillary thyroid micro-carcinoma in the high-risk surgical patient. Thyroid Disorders Ther 2015;4:1000167 
  14. Zhang M, Luo Y, Zhang Y, Tang J. Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low-risk papillary thyroid microcarcinoma: a prospective study. Thyroid 2016;26:1581-1587 
  15. Baek JH, Kim YS, Sung JY, Choi H, Lee JH. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 2011;197:W331-W336 
  16. Mauri G, Cova L, Tondolo T, Ierace T, Baroli A, Di Mauro E, et al. Percutaneous laser ablation of metastatic lymph nodes in the neck from papillary thyroid carcinoma: preliminary results. J Clin Endocrinol Metab 2013;98:E1203-E1207 
  17. Yue W, Chen L, Wang S, Yu S. Locoregional control of recurrent papillary thyroid carcinoma by ultrasound-guided percutaneous microwave ablation: a prospective study. Int J Hyperthermia 2015;31:403-408 
  18. Sun J, Liu X, Zhang Q, Hong Y, Song B, Teng X, et al. Papillary thyroid carcinoma treated with radiofrequency ablation in a patient with hypertrophic cardiomyopathy: a case report. Korean J Radiol 2016;17:558-561 
  19. Kim JH, Baek JH, Sung JY, Min HS, Kim KW, Hah JH, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: preliminary results for patients ineligible for surgery. Int J Hyperthermia 2017;33:212-219 
  20. Yan L, Lan Y, Xiao J, Lin L, Jiang B, Luo Y. Long-term outcomes of radiofrequency ablation for unifocal low-risk papillary thyroid microcarcinoma: a large cohort study of 414 patients. Eur Radiol 2021;31:685-694 
  21. van Dijk SPJ, Coerts HI, Gunput STG, van Velsen EFS, Medici M, Moelker A, et al. Assessment of radiofrequency ablation for papillary microcarcinoma of the thyroid: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 2022;148:317-325 
  22. Yan L, Zhang M, Song Q, Luo Y. Ultrasound-guided radiofrequency ablation versus thyroid lobectomy for low-risk papillary thyroid microcarcinoma: a propensity-matched cohort study of 884 patients. Thyroid 2021;31:1662-1672 
  23. Lan Y, Luo Y, Zhang M, Jin Z, Xiao J, Yan L, et al. Quality of life in papillary thyroid microcarcinoma patients undergoing radiofrequency ablation or surgery: a comparative study. Front Endocrinol (Lausanne) 2020;11:249 
  24. Song Q, Gao H, Ren L, Tian X, Lan Y, Yan L, et al. Radiofrequency ablation versus total thyroidectomy in patients with papillary thyroid microcarcinoma located in the isthmus: a retrospective cohort study. Int J Hyperthermia 2021;38:708-714 
  25. Yan L, Zhang M, Song Q, Xie F, Luo Y. Clinical outcomes of radiofrequency ablation for multifocal papillary thyroid microcarcinoma versus unifocal papillary thyroid microcarcinoma: a propensity-matched cohort study. Eur Radiol 2022;32:1216-1226 
  26. He H, Song Q, Lan Y, Yan L, Xiao J, Zhang Y, et al. Efficacy and safety of ultrasound-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma in patients aged 55 years or older: a retrospective study. Int J Hyperthermia 2021;38:604-610 
  27. Xiao J, Zhang M, Zhang Y, Yan L, Lan Y, Zhu Y, et al. Efficacy and safety of ultrasonography-guided radiofrequency ablation for the treatment of T1bN0M0 papillary thyroid carcinoma: a retrospective study. Int J Hyperthermia 2020;37:392-398 
  28. Xiao J, Zhang Y, Zhang M, Xie F, Yan L, Luo Y, et al. Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study. Int J Hyperthermia 2021;38:402-408 
  29. Ha SM, Sung JY, Baek JH, Na DG, Kim JH, Yoo H, et al. Radiofrequency ablation of small follicular neoplasms: initial clinical outcomes. Int J Hyperthermia 2017;33:931-937 
  30. Lin WC, Tung YC, Chang YH, Luo SD, Chiang PL, Huang SC, et al. Radiofrequency ablation for treatment of thyroid follicular neoplasm with low SUV in PET/CT study. Int J Hyperthermia 2021;38:963-969 
  31. Jeong SY, Baek JH, Choi YJ, Chung SR, Sung TY, Kim WG, et al. Radiofrequency ablation of primary thyroid carcinoma: efficacy according to the types of thyroid carcinoma. Int J Hyperthermia 2018;34:611-616 
  32. Park KW, Shin JH, Han BK, Ko EY, Chung JH. Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol 2011;18:2564-2568 
  33. Choi Y, Jung SL, Bae JS, Lee SH, Jung CK, Jang J, et al. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: a single-center propensity score matching study. Int J Hyperthermia 2019;36:359-367 
  34. Chung SR, Baek JH, Choi YJ, Lee JH. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. Eur Radiol 2019;29:4897-4903 
  35. Yang Z, Yan L, Xiao J, Li W, Li X, Li Y, et al. Long-term results of radiofrequency ablation for locally recurrent papillary thyroid carcinoma. Int J Hyperthermia 2023;40:2191912 
  36. Tang W, Tang X, Jiang D, Zhang X, Wang R, Niu X, et al. Safety and efficacy of thermal ablation for cervical metastatic lymph nodes in papillary thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022;13:967044 
  37. Lee J, Soh EY. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors. Ann Surg 2010;251:114-119 
  38. Osorio M, Moubayed SP, Su H, Urken ML. Systematic review of site distribution of bone metastases in differentiated thyroid cancer. Head Neck 2017;39:812-818 
  39. Luigi Cazzato R, Auloge P, De Marini P, Rousseau C, Chiang JB, et al. Percutaneous image-guided ablation of bone metastases: local tumor control in oligometastatic patients. Int J Hyperthermia 2018;35:493-499 
  40. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142 
  41. Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol 2012;13:117-125 
  42. Garberoglio R, Aliberti C, Appetecchia M, Attard M, Boccuzzi G, Boraso F, et al. Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement. J Ultrasound 2015;18:423-430 
  43. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2017 thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J Radiol 2018;19:632-655 
  44. Mauri G, Hegedus L, Bandula S, Cazzato RL, Czarniecka A, Dudeck O, et al. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J 2021;10:185-197 
  45. Orloff LA, Noel JE, Stack BC Jr, Russell MD, Angelos P, Baek JH, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: an international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head Neck 2022;44:633-660 
  46. Tufano RP, Pace-Asciak P, Russell JO, Suarez C, Randolph GW, Lopez F, et al. Update of radiofrequency ablation for treating benign and malignant thyroid nodules. The future is now. Front Endocrinol (Lausanne) 2021;12:698689 
  47. Lin WC, Chen WC, Wang PW, Chan YC, Chang YH, Chen HS, et al. 2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation. Ultrasonography 2023;42:357-375 
  48. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20:925-951 
  49. Ha EJ, Chung SR, Na DG, Ahn HS, Chung J, Lee JY, et al. 2021 Korean thyroid imaging reporting and data system and imaging-based management of thyroid nodules: Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol 2021;22:2094-2123 
  50. Kim EK. RE: papillary thyroid carcinoma treated with radiofrequency ablation in a patient with hypertrophic cardiomyopathy: a case report. Korean J Radiol 2016;17:965 
  51. Mauri G, Sconfienza LM. Image-guided thermal ablation might be a way to compensate for image deriving cancer overdiagnosis. Int J Hyperthermia 2017;33:489-490 
  52. Sun W, Zhang H, He L, Zhang T, Wang Z, Dong W, et al. Surgery after ultrasound-guided radiofrequency ablation for papillary thyroid carcinoma in 21 patients: a retrospective study from a single center in China. Med Sci Monit 2020;26:e928391